Sažetak
Uvod/Cilj. Kritično oboleli pacijenti imaju veliki rizik od razvoja teških infekcija u jedinicama intenzivne terapije (JIT). Nivo prokalcitonina (PCT) u cirkulaciji je povišen kod bolesnika sa bakterijskom sepsom, tako da PCT može biti koristan u praćenju antibiotske terapije. Cilj ove studije bio je da se ustanove faktori koji utiču na ishod i troškove lečenja u JIT u našoj ustanovi sa posebnim naglaskom na uticaj korišćenja serumskog nivoa PCT u vođenju antimikrobne terapije. Metode. Studija je sprovedena od avgusta 2010. godine do maja 2012. godine u Jedinici intenzivne terapije Klinike za anesteziologiju i intenzivnu terapiju Vojnomedicinske akademije (VMA) u Beogradu, Srbija. Svi kritično oboleli sa sepsom i/ili traumom koji su primljeni u JIT bili su uključeni u studiju. Studijom su obuhvaćeni samo troškovi antimikrobne terapije u JIT i troškovi PCT analize. Koristili smo cenovnik VMA za 2012. godinu. PCT u serumu je meren tehnikom homogenog imunoeseja na Brams Kriptor analizatoru. Rezultati. Studijom su bila obuhvaćena 102 bolesnika. Prosečna starost bolesnika iznosila je 55 ± 19 godina, a 61,8% bolesnika bili su muškarci. Prosečna dužina boravka u JIT (lenght of stay – LOS) iznosila je 12 ± 21 dana. Postojala je statistički značajna razlika (p < 0.001) između ishoda lečenja u grupi sa sepsom u odnosu na grupu sa traumom. Bolesnici mlađi od 70 godina imali su bolju šansu da prežive. Dužina boravka, upotreba karbapenema i merenje PCT uticali su na cenu terapije u JIT. Zaključak. Dobijeni rezultati pokazuju da su godine života, dijagnoza i pol bili glavni prediktori preživljavanja kritično obolelih u JIT. Cena terapije zavisila je od dužine boravka u JIT, upotrebe karbapenema i merenja PCT, ali uticaj ovih faktora na ishod lečenja nije dostigao statističku značajnost.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Wilke MH. Multiresistant bacteria and current therapy: The economical side of the story. Eur J Med Res 2010; 15(12): 571−6.
Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44(10): 1009−34.
Marik PE. Surviving sepsis: going beyond the guidelines. Ann Intensive Care 2011; 1(1): 17.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348(16): 1546−54.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7): 1303−10.
Vincent J, Sakr Y, Sprung CL, Ranieri MV, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34(2): 344−53.
Sharma S, Kumar A. Antimicrobial management of sepsis and septic shock. Clin Chest Med 2008; 29(4): 677−87.
Surbatovic M, Jevdjic J, Veljovic M, Popovic N, Djordjevic D, Radakovic S. Immune Response in Severe Infection: Could Life-Saving Drugs Be Potentially Harmful. ScientificWorldJournal 2013; 2013: 961852.
Cavaillon J, Annane D. Compartmentalization of the inflamma-tory response in sepsis and SIRS. J Endotoxin Res 2006; 12(3): 151−70.
Delinger PR, Levy MM, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013; 41(2): 580−620.
Dellinger PR, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management for severe sepsis and septic shock: 2008. Crit Care Med 2008; 36(1): 296−327.
Patil VK, Morjaria JB, de Villers F, Babu SK. Associations be-tween procalcitonin and markers of bacterial sepsis. Medicina (Kaunas) 2012; 48(8): 383−7.
Maki DG. Microbiologic diagnosis of blood culture-negative sepsis by hemofiltration. Crit Care Med 2004; 32(4): 1075−7.
Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procal-citonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7(3): 210−7.
Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39(9): 2048−58.
Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections: hope for hype. Swiss Med Wkly 2009; 139(23−24): 318−26.
Bouadma L, Luyt C, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375(9713): 463−74.
Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I. The costs of septic syndromes in the inten-sive care unit and influence of hospital-acquired sepsis. Inten-sive Care Med 2003; 29(9): 1464−71.
Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis com-paring meropenem with imipenem plus cilastatin in the treat-ment of severe infections in intensive care. Eur J Health Econ 2006; 7(1): 72−8.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31(4): 1250−6.
Spiegel MR. Theory and problems of probability and statistics. New York: McGraw-Hill; 1992.
Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999; 27(9): 1760−7.
Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136(5): 1237−48.
Lee H, Doig CJ, Ghali WA, Donaldson C, Johnson D, Manns B. Detailed cost analysis of care for survivors of severe sepsis. Crit Care Med 2004; 32(4): 981−5.
Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Se-vransky JE. Long-term mortality and quality of life in sepsis: A systematic review. Crit Care Med 2012; 38(5): 1276−83.
Burchardi H, Schneider H. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost ef-fectiveness of therapy. Pharmacoeconomics 2004; 22(12): 793−813.
Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, et al. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoe-conomics 2008; 26(5): 425−34.
Edwards SJ, Wordsworth S, Clarke MJ. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam. Eur J Health Econ 2012; 13(2): 181−92.
Hsueh P, Liu C, Shi Z, Lee M, Chang F, Yang M. Cost minimisa-tion analysis of antimicrobial treatment for intra-abdominal in-fections: a multicentre retrospective study from Taiwan. Int J Antimicrob Agents 2010; 35(1): 94−6.
Attanasio E, Russo P, Carunchio G, Basoli A, Caprino L. Cost-Effectiveness Study of Imipenem/Cilastatin versus Merope-nem in Intra-Abdominal Infections. Dig Surg 2000; 17(2): 164−72.
Cheval C, Timsit JF, Garrouste-Orgeas M, Assicot M, de Jonghe B, Misset B, et al. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill pa-tients. Intensive Care Med 2000; 26(Suppl 2): S153−8.
Honh A, Schroeder S, Gehn A, Bernhardt K, Bein B, Wegscheider K. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis 2013; 13: 158.
Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011; 397(7): 1792−9.
Adrie C, Alberti C, Chaix-Couturier C, Azoulay E, de Lassence A, Cohen Y, et al. Epidemiology and economic evaluation of se-vere sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as de-terminants of workload and cost. J Crit Care 2005; 20(1): 46−58.
Kollef MH, Golan Y, Micek ST, Shorr AF, Restrego MI. Apprasing contemporary strategies to combat multidrug resistant gram-negative bacterial infections-Proceedings and data from the Gram-Negative Resistance Summit. Clin Infec Dis 2011; 53(Suppl 2): 33−55.
Fraimow HS. Chipping away at unnecessary antibiotic use in the ICU, one day and one study at a time. Crit Care Med 2013; 41(10): 2447−8.
Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents 2008; 31(2): 161−5.